ijms-logo

Journal Browser

Journal Browser

Molecular Advances and Views in Triple-Negative Breast Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 336

Special Issue Editor


E-Mail Website
Guest Editor
Breast Unit, Rea Maternity Hospital, P. Faliro, 17564 Athens, Greece
Interests: breast cancer; hormone receptors; triple negative; HER-2/neu; pregnancy-associated breast cancer; gene mutations
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes of breast malignancies, accounting for approximately 15–20% of all breast cancers and disproportionately affecting younger women and certain ethnic groups. Characterized by the absence of estrogen receptor, progesterone receptor, and HER2 amplification, TNBC lacks the benefit of established targeted therapies, such as endocrine or HER2-directed treatment. Historically, cytotoxic chemotherapy has represented the cornerstone of management. However, recent molecular discoveries and translational advances are reshaping the therapeutic landscape.

Advances in genomic and transcriptomic profiling have highlighted the heterogeneity of TNBC. Subclassification into basal-like, mesenchymal, immunomodulatory, and luminal androgen receptor (LAR) subtypes has provided a molecular framework to understand differential biology and therapeutic vulnerabilities. This stratification not only guides biomarker discovery but also paves the way for approaches involving precision medicine.

For this Special Issue, we welcome original research articles and reviews.

Aim: The aim of this editorial is to highlight recent molecular insights into triple-negative breast cancer (TNBC), underscore how these advances are reshaping therapeutic strategies, and provide perspectives on future directions in research and clinical management.

Research areas may include (but are not limited to) the following: emerging therapeutic targets; biomarker development and precision oncology; and future perspectives.

We look forward to receiving your contributions.

Dr. Ioannis Boutas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • molecular biology
  • personalized medicine
  • triple-negative breast cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 2118 KB  
Article
Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer
by Amy L. Paulson, Radwa M. Elmorsi, Adam M. Lee and R. Stephanie Huang
Int. J. Mol. Sci. 2025, 26(20), 10243; https://doi.org/10.3390/ijms262010243 - 21 Oct 2025
Viewed by 267
Abstract
Triple-negative breast cancer (TNBC) is an aggressive, heterogeneous subtype of breast cancer with limited treatment options. Our previous work explored repurposing selinexor, an XPO1 inhibitor, as a novel therapeutic option for TNBC. To enhance its efficacy, this study aimed to identify beneficial combination [...] Read more.
Triple-negative breast cancer (TNBC) is an aggressive, heterogeneous subtype of breast cancer with limited treatment options. Our previous work explored repurposing selinexor, an XPO1 inhibitor, as a novel therapeutic option for TNBC. To enhance its efficacy, this study aimed to identify beneficial combination therapies with selinexor and experimentally evaluate their effects in TNBC. Using the computational tool IDACombo, we nominated drugs predicted to improve the efficacy of XPO1 inhibition. The top candidate, parthenolide, was tested in vitro using three transcriptionally distinct TNBC cell lines. Fluorescently labeled cells were co-cultured and treated with selinexor, parthenolide, or their combination. Growth inhibition was assessed across the mixed population and by individual cell line after 96 h, and potential synergy was evaluated using Combenefit. While selinexor and parthenolide monotherapy inhibited the growth of TNBC subtypes, the combination was more effective in suppressing the overall cell population. Synergistic interactions between the two agents were observed in specific TNBC lines but not all, reflecting the combination effect in heterogeneous TNBC patients. Our findings suggest the selinexor–parthenolide combination as a potential therapeutic strategy for TNBC, warranting further investigation. Our study also demonstrates the value of integrative computational–experimental approaches in guiding heterogeneity-informed drug combinations for preclinical evaluation. Full article
(This article belongs to the Special Issue Molecular Advances and Views in Triple-Negative Breast Cancer)
Show Figures

Figure 1

Back to TopTop